echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > East Sunshine is about to take the first copy of Liglitin

    East Sunshine is about to take the first copy of Liglitin

    • Last Update: 2020-07-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pharmaceutical Network July 8th, recently, The East Sunshine Drug's Ligretin tablets (acceptance number CYHS1800162) imitation 4 categories of listing applications into the administrative approval stage, the first imitation is about to be taken downAccording to Minnet.com, sales of Ligretin tablets at the end of China's public medical institutions in 2019 were 246 million yuanIt is worth mentioning that since the domestic listing of Ligretin tablets in the domestic market sales, the annual growth rate of more than 100%Liglitin is a dipeptide-4 (DPP-4) inhibitor that improves blood glucose control in patients with type 2 diabetesThe Liglitin tablets were developed by Bollinger Ingham Pharmaceuticals and were approved for import by the State Drug Administration in 2013According to The Inner Net, sales of Ligretin tablets at the
    end sepsis of publichospitals in China in 2019 were 246 million yuan, as were publichospitals in China, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions)It is worth mentioning that since the domestic listing of Ligretin tablets in the domestic market sales, the annual growth rate of more than 100%China's public medical institutions terminal Ligretin tablet sales (units: 10,000 yuan)THE rapid oral absorption of DPP-4 inhibitors, the current domestic has been approved for listing of DPP-4 inhibitors have 5, respectively, Siglitin, Sagretin, Viglitin, Liglitin and AglitinLiglitin is currently the lowest level of renal excretion of DPP-4 inhibitors, is the first approved DPP-4 inhibitor without reducing doses based on renal functionOf the five DPP-4 inhibitors, Sigretin, Sagretin, Vigretin and Agretin have all been approved for saleEast Sunshine's listapplication for ligretin tablets entered the CDE Review Center in July 2018, was given priority review in September 2018 on the grounds that "the same production line is produced and is listed in the United States or the European Union", and the status changed to "in approval" on July 1, 2020, will be taken to the lead copy of the Liglitin tabletSource: Minnet Database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.